Get the Stockscreener App
34.69
1.36%
-0.48
After Hours:
34.65
-0.04
-0.12%
Smith Nephew Plc Adr stock is traded at $34.69, with a volume of 734.83K.
It is down -1.36% in the last 24 hours and up +2.33% over the past month.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
See More
Previous Close:
$35.17
Open:
$34.21
24h Volume:
734.83K
Relative Volume:
1.03
Market Cap:
$14.72B
Revenue:
$5.81B
Net Income/Loss:
$412.00M
P/E Ratio:
36.90
EPS:
0.94
Net Cash Flow:
-
1W Performance:
+1.61%
1M Performance:
+2.33%
6M Performance:
-2.28%
1Y Performance:
+37.39%
1-Day Range:
$34.20
$34.72
1-Week Range:
$33.75
$35.35
52-Week Range:
$23.91
$38.79
Smith Nephew Plc Adr Stock (SNN) Company Profile
Compare SNN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
34.69 | 14.93B | 5.81B | 412.00M | 0 | 0.94 |
|
ABT
Abbott Laboratories
|
110.83 | 189.68B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
358.29 | 138.60B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
102.90 | 131.98B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
76.27 | 115.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.71 | 45.32B | 5.88B | 1.34B | 799.60M | 2.3489 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-14-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Mar-12-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-24 | Downgrade | Berenberg | Buy → Hold |
| Nov-01-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-24 | Initiated | Deutsche Bank | Buy |
| Jun-05-24 | Upgrade | UBS | Neutral → Buy |
| Nov-28-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-03-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-31-23 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-13-23 | Initiated | Stifel | Hold |
| Aug-08-23 | Upgrade | UBS | Sell → Neutral |
| Apr-27-23 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-12-22 | Initiated | Citigroup | Buy |
| Nov-28-22 | Downgrade | UBS | Neutral → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-28-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-15-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-22 | Upgrade | Redburn | Sell → Neutral |
| Jun-09-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-18-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-01-20 | Initiated | Barclays | Overweight |
| Jul-29-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-21-19 | Initiated | Citigroup | Buy |
| Nov-12-19 | Initiated | Bernstein | Outperform |
| Jul-23-19 | Upgrade | Berenberg | Hold → Buy |
| Feb-08-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Jan-02-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-01-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-25-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-11-17 | Initiated | Canaccord Genuity | Buy |
| Feb-27-17 | Downgrade | Goldman | Buy → Neutral |
| Jan-19-17 | Initiated | HSBC Securities | Hold |
| Dec-08-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-06-16 | Downgrade | Berenberg | Buy → Hold |
| Feb-26-16 | Initiated | Cantor Fitzgerald | Hold |
View All
Smith Nephew Plc Adr Stock (SNN) Latest News
Orthopedic Implants Market Size to Reach USD 33.20 Billion by 2033, Driven by Rising Musculoskeletal Disorders and Surgical Innovation – SNS Insider - GlobeNewswire Inc.
Jim Cramer on Smith & Nephew: "This Group, I Do Not Like" - Finviz
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair - Finviz
The Truth About Smith & Nephew plc: Why This ‘Boring’ Med-Tech Stock Might Be Your Sneaky Power - AD HOC NEWS
Smith & Nephew ADR trying to close in on key technical benchmark - MSN
The Truth About Smith & Nephew plc (ADR): Wall Street Sleeper Stock or Total Snooze? - AD HOC NEWS
Smith & Nephew plc (ADR): Quiet Charts, Cautious Optimism – Is SNN a Sleeper in Medtech? - AD HOC NEWS
Smith & Nephew (SN, SNN) Stock Outlook for December 2025: Q3 Setback, $500m Buyback and What Comes Next - ts2.tech
Smith and Nephew (LON:SN) positioned across FTSE 100 Today healthcare landscape - Kalkine Media
FTSE 100 today: Pound lower; Magnum debuts, Smith & Nephew sets new goals - Investing.com
Smith & Nephew Unveils RISE Blueprint for a Stronger Future - Kalkine Media
Smith+Nephew sets ambitious growth targets through 2028 - Investing.com
Smith & Nephew (SNN) Stock Forecast 2026: Q3 2025 Results, $500m Buyback and New Board Signals - TechStock²
Smith & Nephew PLC (NYSE:SNN): A Value Investment in Medical Devices - Chartmill
[6-K] SMITH & NEPHEW PLC Current Report (Foreign Issuer) | SNN SEC FilingForm 6-K - Stock Titan
Smith & Nephew PlcDirector/PDMR Shareholding - Research Tree
REGSmith & Nephew PlcDirector/PDMR Shareholding - TradingView
Smith & Nephew stock initiated with Buy rating at Kepler Cheuvreux - Investing.com
Shell Stock Price Today (12 Nov 2025): SHEL ADR edges lower as oil slides; London closes at 2,909p amid fresh buyback and Volta Media sale - ts2.tech
Smith+Nephew shares tumble as Q3 sales miss expectations - Investing.com
Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $36.75 - Defense World
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT - Sahm
Predictions - sharewise.com
UFC® and Smith+Nephew announce multi-year extension of partnership - The Globe and Mail
Smith & Nephew stock price target raised to GBP17 by RBC on growth outlook - Investing.com Australia
Smith & Nephew schedules third quarter trading report release for November 6 - Investing.com
BlackRock Adjusts Voting Rights in Smith & Nephew - The Globe and Mail
Smith & Nephew stock rating downgraded by Bernstein as valuation recovers - Investing.com
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant - Sahm
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention - Sahm
Smith & Nephew’s ratings affirmed by Moody’s with positive outlook - Investing.com
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty - The Globe and Mail
Park Avenue Securities LLC Acquires 583 Shares of Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew CFO John Rogers relocates to US, receives revised compensation - Investing.com
Citi Keeps Their Hold Rating on Koninklijke Philips N.V. (0LNG) - The Globe and Mail
Smith & Nephew (LON:SN) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Smith Nephew Plc Adr Stock (SNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
2.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):